Status:
COMPLETED
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
Brief Summary
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to monitor the safety...
Eligibility Criteria
Inclusion
- Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH) and/or that, according to the Physician, their symptoms require medical treatment to improve their quality of life. The patients could be naïve to treatment or could be on treatment with other drugs but have not responded adequately to treatment. This study is non-interventional, so the decision to treat must be based on the best standard accepted clinical practice, and according to Secotex® prescribing information
Exclusion
- Patients with known hypersensitivity to Tamsulosin, or any other component of the product
- Patients with a history of orthostatic hypotension or severe liver failure
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
982 Patients enrolled
Trial Details
Trial ID
NCT02245529
Start Date
March 1 2005
Last Update
September 19 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.